Hepatitis B "immune" globulin: effectiveness in prevention of dialysis-associated hepatitis.
A randomized, double-blind, multicenter study of hepatitis prevention by immune serum globulin with high anti-HBs titer ("hepatitis B immune globulin") was carried out among 318 new patients and 296 staff members of renal dialysis units. Three milliliters of high titer globulin, repeated at four months, was compared with equal doses of intermediate or normal titer globulin. Among staff members, the cumulative percentages developing hepatitis or HBs Ag, or both, within eight months were 6.9, 11.7, and 11.1 in the high, intermediate, and normal titer groups respectively. The lower incidence associated with high titer globulin was not significant (P greater than 0.05). However, among the patients the respective percentages were 7.9, 21.3, and 23.1 and the lower incidence in the high titer globulin group was significant.
D000906:Antibodies; D002353:Carrier State / Q000453:epidemiology; D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000517:prevention & control; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000008:administration & dosage; D006511:Hepatitis B Antigens / Q000032:analysis; D006757:Hospital Units; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D008505:Medical Staff, Hospital; D006435:Renal Dialysis / Q000009:adverse effects
D000906:Antibodies; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D007136:Immunoglobulins